XTX Topco Ltd Acquires Shares of 8,054 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

XTX Topco Ltd acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 8,054 shares of the biopharmaceutical company's stock, valued at approximately $316,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of XENE. State Street Corp increased its stake in shares of Xenon Pharmaceuticals by 13.2% during the 3rd quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company's stock worth $11,004,000 after purchasing an additional 32,701 shares in the last quarter. Barclays PLC grew its holdings in Xenon Pharmaceuticals by 1,275.5% during the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $590,000 after buying an additional 13,903 shares during the last quarter. JPMorgan Chase & Co. increased its position in Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after buying an additional 905,129 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Xenon Pharmaceuticals by 3.7% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,818 shares of the biopharmaceutical company's stock worth $1,953,000 after acquiring an additional 1,755 shares during the last quarter. Finally, Elmwood Wealth Management Inc. lifted its position in shares of Xenon Pharmaceuticals by 44.7% in the fourth quarter. Elmwood Wealth Management Inc. now owns 11,007 shares of the biopharmaceutical company's stock valued at $431,000 after acquiring an additional 3,400 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. The Goldman Sachs Group dropped their price objective on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. HC Wainwright reissued a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. StockNews.com raised shares of Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 target price for the company. Finally, Royal Bank of Canada restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $56.78.

Xenon Pharmaceuticals Price Performance

XENE stock traded up $0.22 during trading on Monday, reaching $37.84. 502,152 shares of the stock traded hands, compared to its average volume of 444,702. The firm has a market capitalization of $2.90 billion, a PE ratio of -13.42 and a beta of 1.21. The business's 50 day moving average price is $34.80 and its 200-day moving average price is $38.66. Xenon Pharmaceuticals Inc. has a 52-week low of $26.74 and a 52-week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.05. On average, equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.